In summary, the present study shows that plasma BDNF levels are positively correlated with clinical improvement in patients who undergo remission, and that patients who are refractory to treatment have higher plasma BDNF levels than patients who achieve remission at the initial depressive syndrome stage. This evidence concerns the gene BDNF and depressive disorder.